In Vivo CAR-T Receives Oral Presentation, EBV-mRNA Tumor Therapeutic Vaccine Combination Therapy Featured in Poster Presentation
ChengduMay 31, 2026 /PRNewswire/ — Recently, Weisheng Biotech announced that two of its innovative research achievements have been selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Among them, the in vivo CAR-T project WGb-0301 has been selected for a Rapid Oral presentation, and the study on the EBV-associated tumor therapeutic mRNA vaccine WGc-043 combined with PD-1 antibody for treating relapsed/refractory lymphoma has been selected for a Poster presentation, demonstrating the company’s innovation capabilities and international influence in the fields of mRNA drugs, LNP delivery, and next-generation cell therapy.
Weisheng Biotech
First Human Study Data Released:In Vivo CAR-T ProjectReceives ASCO Oral Presentation
Based on Weisheng Biotech’s proprietary CD8-targeted lipid nanoparticle (CD8-tLNP) platform, using mRNA delivery technology, anti-CD19 CAR-T cells are generated in situ within patients for the treatment of relapsed/refractory B-cell lymphoma. Compared with traditional ex vivo CAR-T preparation, in vivo CAR-T technology eliminates the need for complex ex vivo cell isolation and expansion processes, as well as lymphodepletion preconditioning, offering potential advantages such as being “off-the-shelf,” shorter treatment cycles, lower costs, and greater ease of large-scale adoption.
According to the first-in-human study data disclosed at this ASCO, the project has demonstrated positive safety and preliminary efficacy signals in patients with relapsed/refractory B-cell lymphoma. The study shows: All patients rapidly induced CAR expression within 4 to 6 hours after dosing, achieving deep B-cell depletion, with CAR positivity rates reaching up to 100%, including one patient who achieved complete remission (CR); successful repeated dosing up to 10 times, with patients showing good overall tolerability, all treatment-related adverse events being Grade 1 to 2, and no Grade ≥3 TRAEs occurring.
WGc-043 Combined with PD-1 Shows Positive Clinical Potential in Lymphoma Treatment
Another study selected for the ASCO Poster focuses on Weisheng Biotech’s proprietary EBV-associated tumor therapeutic mRNA vaccine WGc-043 combined with the PD-1 antibody Tislelizumab, for treating relapsed/refractory extranodal NK/T-cell lymphoma. Study data show that among 5 evaluable patients, 3 achieved complete remission (CR), and all patients who achieved CR remain in remission, indicating favorable clinical potential. The combination regimen was well tolerated overall, with all treatment-related adverse events being Grade 1 and no Grade ≥3 TRAEs occurring.
Behind the Two ASCO Achievements: Clinically Validated LNP Platform andLarge-Scale ManufacturingCapabilities
The simultaneous selection of both studies for ASCO is underpinned by support from Weisheng Biotech’s proprietary lipid nanoparticle (LNP) delivery platform.
As a key delivery vehicle for nucleic acid drugs, LNP directly determines drug delivery efficiency, safety, storage stability, and clinical translation potential. After over a decade of continuous R&D, Weisheng Biotech has established a complete technology system based on proprietary AI algorithms for novel ionizable lipid design, mRNA sequence optimization, formulation development, and large-scale production, with core independent intellectual property rights (with FTO).
Based on its proprietary LNP delivery platform, Weisheng Biotech has developed multiple therapeutic drugs that have entered clinical trials, collecting data from hundreds of patients (via intramuscular or intravenous administration), demonstrating good safety and tolerability. Currently, it has obtained 1 Phase II clinical trial approval and 6 Phase I clinical trial approvals in China, the United States, and other countries. Weisheng Biotech’s in vivo CAR-T platform is exploring benefits for tumor patients and autoimmune disease patients in clinical trials. In addition to the CD19 target featured in this ASCO oral presentation, CD20 and BCMA have also entered clinical trials, and the CD19/BCMA dual-target in vivo CAR-T project is about to enter clinical trials.
In terms of large-scale manufacturing capabilities, Weisheng Biotech has built GMP-compliant production facilities, with integrated development and production capabilities ranging from targeted antibodies (CD3, CD5, CD7, CD8, etc.), plasmids, mRNA drug substance to LNP formulations, meeting clinical research needs. Leveraging its independently controllable R&D and manufacturing platform, the company is continuously advancing the development and global collaboration of innovative products such as tumor therapeutic vaccines, in vivo CAR-T, and mRNA-encoded antibodies.
In recent years, Weisheng Biotech has consistently focused on areas including mRNA drugs, LNP delivery systems, targeted delivery (tLNP), and in vivo cell therapy, with a product pipeline covering fields such as oncology, autoimmune diseases, obesity, and aging. The simultaneous presentation of these two studies at ASCO also marks that Weisheng Biotech’s technological accumulation in the direction of “mRNA + precision delivery + in vivo cell therapy” is gradually entering the international clinical validation stage.
Looking ahead, Weisheng Biotech will continue to advance the clinical development and international collaboration of these projects, exploring safer, more effective, and more accessible next-generation treatment options, bringing more innovative treatment choices to patients worldwide.